← Leaderboards
Hisashi Harada
Virginia Commonwealth University
$3,277,011
Attributed
$6,565,403
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,565,403 · 6
By mechanism
R01$5,554,136 · 3
R41$461,186 · 1
R21$394,831 · 1
R03$155,250 · 1
Top collaborators
- David A. Gewirtz14 shared
- Joseph William Landry14 shared
- Matthew C Hartman2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Joseph William Landry$2,951,878
- David A. Gewirtz$3,700,163
- Chunhao Li$16,149,141
- Paul Dent$11,860,656
- Brad E. Windle$1,995,833
Others in their field
Top investigators on “Cell Death”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Gregory H Reaman · National Childhood Cancer Foundation$155,748,965
- David R. Weir · University Of Michigan At Ann Arbor$155,654,998
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- William George Nelson · Johns Hopkins University$85,651,800
Research focus
Cell DeathMouse ModelIn VitroApoptoticBcl1 OncogeneMalignant NeoplasmsTumorProtein FamilyCellsMediatingCell Culture TechniquesPreventPre-ClinicalCharacteristicsToxic EffectResponseAnimalsSiteTherapeutic AgentsClinical TrialsDesignNeoplastic CellApoptosisDose
Grant awards (24)
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$517,388
R01 · FY2025 · CA
Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.$55,000
R41 · FY2025 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$491,519
R01 · FY2024 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$45,933
R01 · FY2024 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2023 · CA
Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.$406,186
R41 · FY2023 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$273,905
R01 · FY2023 · CA
Targeting gain-of-function p53 and BCL-2 for small cell lung cancer treatment$213,383
R21 · FY2023 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$66,687
R01 · FY2023 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$43,892
R01 · FY2023 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2022 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$386,245
R01 · FY2022 · CA
Targeting gain-of-function p53 and BCL-2 for small cell lung cancer treatment$181,448
R21 · FY2022 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$56,404
R01 · FY2022 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$509,377
R01 · FY2021 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2021 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2020 · CA
Targeting BCL-2 family-regulated cell death for HNSCC treatment$77,625
R03 · FY2020 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2019 · CA
Targeting BCL-2 family-regulated cell death for HNSCC treatment$77,625
R03 · FY2019 · CA · contact PI
Apoptosis Induced by Glucocorticoids and MEK1/2 Inhibitors in Leukemia$237,412
R01 · FY2012 · CA · contact PI
Apoptosis Induced by Glucocorticoids and MEK1/2 Inhibitors in Leukemia$237,412
R01 · FY2011 · CA · contact PI
Apoptosis Induced by Glucocorticoids and MEK1/2 Inhibitors in Leukemia$244,755
R01 · FY2010 · CA · contact PI
Apoptosis Induced by Glucocorticoids and MEK1/2 Inhibitors in Leukemia$247,858
R01 · FY2009 · CA · contact PI